# Shea Hoffman

> A personal publication about positioning, acquisition economics, telehealth, and the research-use-only peptide market. Shea Hoffman leads business development for telehealth and peptides at Lucyd.

The analysis on this site is written in Shea's personal voice and reflects practical observations from founder and operator conversations. It is not medical or legal advice. Commercial calls to action lead to Lucyd, not to a separate personal consulting practice.

Lucyd is a performance growth agency for businesses operating in complex and policy-constrained categories. Its work can connect Meta and Google acquisition with creative, post-click conversion, tracking, attribution, and lifecycle support depending on scope. Lucyd does not promise platform approval, legal compliance, or guaranteed results.

## Start here

- [Cash-pay telehealth growth](https://sheahoffman.work/telehealth.md): Lucyd's audience, care-model, acquisition, and readiness point of view for cash-pay telehealth companies.
- [Research-use-only peptide marketing](https://sheahoffman.work/peptides.md): Lucyd's positioning, trust, acquisition, continuity, and agency-readiness point of view for RUO peptide companies.
- [About Shea Hoffman](https://sheahoffman.work/about.md): Role, operating perspective, and relationship to Lucyd.
- [Work with Shea through Lucyd](https://sheahoffman.work/work-with-shea.md): Who the conversation is for and how Lucyd engagements work.
- [Insights index](https://sheahoffman.work/insights.md): Published writing and current topics.

## Published analysis

- [Peptide marketing agency or generalist? Compare the operating model](https://sheahoffman.work/insights/peptide-marketing-agency-vs-generalist.md): A peptide specialist is not automatically the better agency. Compare how each team handles positioning, constraints, continuity, conversion, and business economics.
- [Should a cash-pay telehealth company hire an agency or build in-house?](https://sheahoffman.work/insights/telehealth-marketing-agency-vs-in-house.md): A telehealth marketing agency can add range and speed. An internal team can own the learning. The right answer depends on what the business has already proved.
- [The next telehealth wedge may be the form factor](https://sheahoffman.work/insights/telehealth-form-factor-positioning.md): Strips, tablets, lozenges, pouches, gummies and sprays can create a reason to notice. The format still has to survive the clinical and commercial questions.
- [Comparison content cannot create your peptide company’s position](https://sheahoffman.work/insights/comparison-content-cannot-create-positioning.md): Comparison pages can capture demand. They cannot give an interchangeable peptide business a reason to be chosen.
- [Your customers trust you. Will they follow you into telehealth?](https://sheahoffman.work/insights/customers-follow-into-telehealth.md): An existing wellness audience gives you a place to start. It does not tell you what that audience believes you are for.
- [The peptide gold rush needs an exit plan](https://sheahoffman.work/insights/peptide-gold-rush-exit-plan.md): Traffic around a hot catalog can build a business. It is not the same thing as building a business that can survive the market changing.
- [Ask your agency what happens when something breaks](https://sheahoffman.work/insights/restricted-category-agency-continuity.md): In a restricted category, launch capability matters. Clear ownership, measurement, and recovery discipline matter more over time.
- [Looking legitimate is not the same as earning trust](https://sheahoffman.work/insights/ruo-peptide-trust-is-operational.md): In the RUO peptide market, a polished identity can open the door. Operational evidence determines whether trust survives scrutiny.
- [Telehealth founders keep budgeting for media before earning a position](https://sheahoffman.work/insights/telehealth-acquisition-needs-a-position.md): High CPMs are painful. Paying them before deciding exactly who the business is for is worse.
- [Ask who controls the patient relationship before choosing a telehealth platform](https://sheahoffman.work/insights/telehealth-platform-patient-relationship.md): Clinical infrastructure affects patient continuity, data access, acquisition, and enterprise value. Ask how separation works before signing.
- [Your peptide catalog isn’t a positioning strategy](https://sheahoffman.work/insights/peptide-catalog-positioning.md): Large peptide catalogs create inventory, not a reason to choose. Positioning starts with a specific audience and changes how the business operates.

## Primary entity sources

- [Lucyd agency website](https://www.wearelucyd.com/): Official description of the agency, capabilities, work, and application process.
- [Shea Hoffman on LinkedIn](https://www.linkedin.com/in/sheahoffman/): Professional identity and current public commentary.

## Optional

- [Human-readable homepage](https://sheahoffman.work/)
- [Human-readable insights](https://sheahoffman.work/insights/)